Dr. Lee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1180 N Indian Canyon Dr
Suite E218
Palm Springs, CA 92262Phone+1 760-992-7217Fax+1 760-992-7217
Education & Training
- University of Southern California/LAC+USC Medical CenterFellowship, Breast Surgical Oncology, 2005 - 2006
- Cooper Medical School of Rowan University/Cooper University HospitalFellowship, Surgical Critical Care, 1998 - 1999
- Cooper Medical School of Rowan University/Cooper University HospitalResidency, Surgery, 1992 - 1998
- University of Tennessee Health Science Center College of MedicineClass of 1992
Certifications & Licensure
- CA State Medical License 2005 - 2024
- VA State Medical License 2004 - 2006
- AL State Medical License 2002 - 2005
- NJ State Medical License 1994 - 2003
- PA State Medical License 1994 - 1994
Clinical Trials
- NBRST: Prospective Neo-adjuvant REGISTRY Trial Start of enrollment: 2011 Jul 01
- PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Publications & Presentations
PubMed
- 23 citationsImpact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant ChemotherapyPaul L. Baron, Peter D. Beitsch, Danielle Boselli, James T. Symanowski, James Pellicane
Annals of Surgical Oncology. 2016-05-01 - 5 citationsAge-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.Pat Whitworth, Peter D Beitsch, James V Pellicane, Paul L Baron, Laura A Lee
Annals of Surgical Oncology. 2022-04-04 - 5 citationsDistinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tum...Pat W Whitworth, Peter D Beitsch, James V Pellicane, Paul L Baron, Laura A Lee
JCO Precision Oncology. 2022-04-01
Press Mentions
- Agendia Presents Broad Spectrum of Data from FLEX Study Highlighting Tumor Heterogeneity Within Underrepresented or Underserved Patient Populations at SABCS 2020December 9th, 2020
- Real-World Data Explores New Gene Expression Profiles in Breast CancerJanuary 31st, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: